MARKET

CWBR

CWBR

CohBar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.360
-0.040
-2.86%
Opening 09:52 05/07 EDT
OPEN
1.400
PREV CLOSE
1.400
HIGH
1.400
LOW
1.360
VOLUME
6.52K
TURNOVER
--
52 WEEK HIGH
3.600
52 WEEK LOW
0.8500
MARKET CAP
84.03M
P/E (TTM)
-4.0308
1D
5D
1M
3M
1Y
5Y
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2021 financial results aft...
GlobeNewswire · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 4d ago
8-K: CohBar, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/27 18:04
BRIEF-Cohbar Appoints Joseph Sarret As Chief Executive Officer And Director
reuters.com · 04/27 13:29
CohBar appoints Joseph Sarret as CEO and Director
CohBar (CWBR) has appointed Joseph J. Sarret, M.D., J.D. as CEO and Director, effective May 3, 2021.In addition, Mr. David Greenwood, a current Director with 40 years of financial and operational
Seekingalpha · 04/27 12:41
CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director
Announces change to the Board of Director’s ChairMENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend heal...
GlobeNewswire · 04/27 12:30
DJ Cohbar Price Target Announced at $3.00/Share by Maxim Group
Dow Jones · 04/23 13:11
DJ Cohbar Initiated at Buy by Maxim Group
Dow Jones · 04/23 13:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CWBR. Analyze the recent business situations of CohBar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CWBR stock price target is 5.83 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 6.07M
% Owned: 9.82%
Shares Outstanding: 61.79M
TypeInstitutionsShares
Increased
24
1.17M
New
12
374.43K
Decreased
5
216.58K
Sold Out
3
244.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.54%
Pharmaceuticals & Medical Research
+1.19%
Key Executives
Chairman/Independent Director
Albion Fitzgerald
Chief Financial Officer/Treasurer/Secretary
Jeffrey Biunno
Chief Scientific Officer
Kenneth Cundy
Director of Investor Relations/IR Contact Officer
Jordyn Tarazi
Director
Jon Stern
Independent Director
Nir Barzilai
Independent Director
Pinchas Cohen
Independent Director
Phyllis Gardner
Independent Director
David Greenwood
Independent Director
Misha Petkevich
No Data
About CWBR
CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.

Webull offers kinds of CohBar Inc stock information, including NASDAQ:CWBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CWBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CWBR stock methods without spending real money on the virtual paper trading platform.